TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer
68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain alive with a median follow-up of […]